Maltais-Payette I, et al. - Whether glutamate level evaluation can help detect individuals with abdominal obesity and high cardiometabolic risk was investigated in this study performed on 99 men and 99 women. Researchers used the Biocrates p180 kit to measure fasting serum glutamate. They also measured anthropometric and metabolic variables to detect people with abdominal obesity [waist circumference (WC) ≥ 95cm in both sexes], the hypertriglyceridemic waist (HTW) phenotype and the metabolic syndrome (MetS). They found a strong correlation of glutamate with WC and various markers of metabolic dysfunction, especially fasting triglyceride level, HDL-cholesterol level and the HOMA-IR index. In logistic regressions, glutamate displayed an excellent accuracy for the detection of people with abdominal obesity (ROC_AUC: 0.90 for both sexes), a good accuracy to recognize those with the HTW phenotype (ROC_AUC: 0.81 for men; 0.85 for women) and fair-to-good accuracy for the MetS (ROC_AUC: 0.78 for men; 0.89 for women). Experts concluded that glutamate level may afford an attractive potential biomarker of abdominal obesity and metabolic risk.